In low- and middle-income countries, many people living with diabetes
struggle to get the care they need. These challenges range from having
medicine in stock at the pharmacy to a lack of trained doctors and
nurses who can effectively diagnose and treat diabetes.
We know from experience that changing diabetes care for the better takes programmes and partnerships - no one organisation can solve the challenge alone.
For more than two decades, we've been partnering to bring solutions that help people access the diabetes care they need, no matter where they live.
In all countries, the BoP project implements an integrated approach
to ensure comprehensive diabetes care for people.
The programs are established as public-private partnerships that promote shared responsibility between Novo Nordisk, governments and local health authorities, in alignment with the United Nations Sustainable Development Goals (SDGs).
Ghana, Kenya, Nigeria & Senegal only
Strengthened Physical Infrastructure
Training of Healthcare Professionals
Stable & Affordable Insulin Supply
Children living with type 1 diabetes in low-income countries are one of the most vulnerable populations who often face the greatest risk associated with inadequate access to insulin and medical care.
In Novo Nordisk, we believe no child should die from diabetes and to address these critical unmet needs, we established the Changing Diabetes® in Children program in 2009. The program is implemented in 14 countries, 10 of which are in Africa.
The Changing Diabetes® in Children program is a public-private partnership program between Novo Nordisk, Roche, the International Society for Paediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). In each country, the program is implemented by a group of local partners and national ministries of health.
The Changing Diabetes® in Children program uses a holistic approach to improve access to quality care and treatment for children living with type 1 diabetes. The program focuses on six areas that address local challenges to ensure impact:
The current ambition is to reach 20,000 children by 2020. By the end of 2019, the program has reached more than 25,000 children and adolescents living with type 1 diabetes.
Novo Nordisk introduced a differential pricing policy to increase low-priced human insulin for least developed countries (LDCs) in 2001, many of which are in Middle Africa countries. In 2019, the scope was updated to include the Access to Insulin Commitment to lower the ceiling price and include humanitarian relief settings.
In addition to the ceiling price for LDCs, Novo Nordisk is committed to working with others to improve the efficiency of supply chains and government procurement and tendering.
For more information visit the access to Insulin commitment page
We are driving change to defeat diabetes and we continue to innovate and invest in sustainable approaches that address gaps in access to care.
For more information, please contact: Abigail Chakava, Public Affairs & Projects Manager, Novo Nordisk, Middle Africa, email@example.com, +254-798-471-705.